Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 12/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11304327 | 0.83 | CYP2D6 (0.47) | PTGS1PTGS2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1020926 | 0.79 | PTGS2 (0.57) | PTGS1PTGS2 | |
| SCHEMBL8266257 | 0.79 | PTGS1 (0.67) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL17480605 | 0.77 | ME2 (0.50) | PTGS1PTGS2HTTALDH1A1HPGD | |
| SCHEMBL1276757 | 0.76 | PTGS1 (0.50) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL12048588 | 0.76 | PTGS1 (0.34) | PTGS1PTGS2 | |
| SCHEMBL1022376 | 0.76 | PTGS1 (0.50) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1339032 | 0.76 | CYP2A6 (0.42) | PTGS1PTGS2ALDH1A1 | |
| SCHEMBL1259640 | 0.74 | PARP10 (0.44) | PTGS1PTGS2ALDH1A1 | |
| SCHEMBL1019980 | 0.73 | PTGS1 (0.48) | PTGS1PTGS2HTTUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | claimed |
| US-9643919-B2 | Cycloalkyl-dione derivatives and methods of their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160031805-A1 | CYCLOALKYL-DIONE DERIVATIVES AND METHODS OF THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031805-A1 | CYCLOALKYL-DIONE DERIVATIVES AND METHODS OF THEIR USE | CYP1B1, SQLE, C1S | PTGS1 1629/4885PTGS2 2224/4885HTT 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.